INTEGRA LIFESCIENCES HOLDINGS CORPIARTEarnings & Financial Report
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
IART Q3 2025 Key Financial Metrics
Revenue
$402.1M
Gross Profit
$207.0M
Operating Profit
$11.8M
Net Profit
$-5.4M
Gross Margin
51.5%
Operating Margin
2.9%
Net Margin
-1.3%
YoY Growth
5.6%
EPS
$-0.07
Financial Flow
INTEGRA LIFESCIENCES HOLDINGS CORP Q3 2025 Financial Summary
INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $402.1M for Q3 2025, with a net profit of $-5.4M (-1.3% margin). Cost of goods sold was $195.1M, operating expenses totaled $195.2M.
Key Financial Metrics
| Total Revenue | $402.1M |
|---|---|
| Net Profit | $-5.4M |
| Gross Margin | 51.5% |
| Operating Margin | 2.9% |
| Report Period | Q3 2025 |
INTEGRA LIFESCIENCES HOLDINGS CORP Annual Revenue by Year
INTEGRA LIFESCIENCES HOLDINGS CORP annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.6B).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.6B |
| 2023 | $1.5B |
| 2022 | $1.6B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $397.0M | $368.9M | $418.2M | $380.8M | $442.6M | $382.7M | $415.6M | $402.1M |
| YoY Growth | -0.2% | -3.1% | 9.7% | -0.4% | 11.5% | 3.7% | -0.6% | 5.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.78B | $4.08B | $4.07B | $4.07B | $4.04B | $4.05B | $3.67B | $3.65B |
| Liabilities | $2.19B | $2.48B | $2.54B | $2.54B | $2.49B | $2.53B | $2.63B | $2.61B |
| Equity | $1.59B | $1.60B | $1.53B | $1.52B | $1.55B | $1.52B | $1.04B | $1.04B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $58.8M | $15.8M | $40.4M | $22.5M | $50.7M | $-11.3M | $8.9M | $40.9M |
